<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552707</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-MT-10-02</org_study_id>
    <nct_id>NCT01552707</nct_id>
  </id_info>
  <brief_title>Safety Study of Mesenchymal Stem Cells and Spinal Fusion</brief_title>
  <official_title>&quot;Ex Vivo&quot; Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue for Spinal Fusion in Spine Degenerative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Ciencia e Innovación, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present prospective, randomized study, compares the spinal fusion obtained after
      instrumentation and the use of a biologic product (patient's mesenchymal cells obtained from
      his/her own bone marrow which will be fixed in human bone tissue form a donor), with the
      current procedure that consists in instrumented spinal fusion and the use of each patient's
      bone obtained from his/her iliac crest.

      The working hypothesis proposes that the tissue engineering is a valid and useful technique
      to achieve bone regeneration, avoiding the need for obtaining patient's iliac crest and its
      associated morbidity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open-label, randomized, parallel, single-dose phase I-II clinical trial in which
      62 patients affected with L4-L5 degenerative spondylolisthesis grade I-II according to
      Meyerding and/or with L4-L5 degenerative discopathy needing spinal fusion will enter the
      trial with the primary objective of assessing the feasibility and safety of &quot;ex-vivo&quot;
      expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion.
      Secondary objectives are to assess the efficacy of the implantation by imaging (computerized
      helicoidal tomography and X-ray) and clinical questionnaires (pain by visual analogue scale,
      quality of life by SF-36 and Oswestry Disability Index).

      Patients will be randomized to one of the two treatment arms (instrumented spinal fusion and
      the tissue engineering product composed by &quot;ex-vivo&quot; expanded autologous mesenchymal stem
      cells fixed in allogenic bone tissue in spinal fusion or the standard treatment of
      instrumented spinal fusion and patient's bone iliac crest). Thereafter, patients will be
      followed for 12 months.

      Imaging assessment will be done by an independent blinded radiologist.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by &quot;ex-vivo&quot; expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be assessed by collecting adverse events throughout the experimental phase, which includes a follow-up of 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of XCEL-MT-OSTEO-ALPHA (composed by &quot;ex-vivo&quot; expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)</measure>
    <time_frame>12 months</time_frame>
    <description>Feasibility will be measured by assessing the percentage of patients to which bone marrow puncture is made are thereafter treated and by checking the cascade of procedures to confirm the global process is viable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy spinal fusion by imaging procedures (X-Ray).</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Spinal fusion will be assessed by spinal X-Ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Spinal fusion will be assessed by the presence of solid bonny bridges using computerized helicoidal tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes (VAS)</measure>
    <time_frame>7 days and at 3, 6 and 12 months</time_frame>
    <description>Pain measurement by visual analogue scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes (SF-36)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>This clinical outcome will measure the quality of life by the self-reported quality of life questionnaire SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome (Oswestry Disability Index)</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>To assess the extent by which a person's functional level is restricted by disability by the Oswestry Disability Index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Lumbar Spondylolisthesis Involving L4-L5, and/or</condition>
  <condition>Degenerative Discopathy Involving L4-L5</condition>
  <arm_group>
    <arm_group_label>XCEL-MT-OSTEO-ALPHA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;ex-vivo&quot; expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Instrumented spinal fusion together with patient's bone iliac crest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XCEL-MT-OSTEO-ALPHA</intervention_name>
    <description>Isolation and &quot;ex-vivo&quot; expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion.</description>
    <arm_group_label>XCEL-MT-OSTEO-ALPHA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Instrumented spinal fusion together with patient's bone iliac crest</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  L4-L5 degenerative spondylolisthesis grade I-II Meyerding isolated or associated to
             more than one level, and/or L4-L5 degenerative discopathy isolated or associated to
             more than one level.

          -  18 to 85 years of age (male and female)

          -  Informed Consent Form signed

          -  The patient is able to understand the nature of the study

        Exclusion Criteria:

          -  Previous spine surgery

          -  L4 isthmic spondylolisthesis

          -  Smoker (more than 10 cigarettes a day)

          -  Systemic or local infection

          -  Patients treated with steroids (oral or systemic) within 3 months of entering the
             study, or treated with biphosphonates for more than 10 years

          -  Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab)
             or Syphilis.

          -  Pregnant woman or intended to become pregnant, or breath feeding

          -  Neoplasia within the previous 5 years, or without remission

          -  Immunosuppressive states (except diabetes mellitus. Treatment with therapies is
             allowed)

          -  Significant abnormal laboratory tests that contraindicates the surgery.

          -  Participation in another clinical trial or treated with an investigational medicinal
             product the previous 3 months

          -  Other pathologic conditions or circumstances that difficult participation in the study
             according to medical criteria

          -  The patient does not accept to be followed-up for a period that could exceed the
             clinical trial length

          -  The patient is legally dependent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Bagó, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc de Salut Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitari Dexeus (ICATME)</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net</url>
    <description>Banc de Sang i Teixits. Xcelia, División de Terapias Avanzadas.</description>
  </link>
  <link>
    <url>http://www.icatme.com</url>
    <description>Institut Català de Traumatologia i Medicina de l'Esport (Institut Universitari Dexeus)</description>
  </link>
  <link>
    <url>http://www.vhebron.net</url>
    <description>Hospital Universitari Vall d'Hebron, Barcelona</description>
  </link>
  <link>
    <url>http://www.gencat.cat/ics/germanstrias/</url>
    <description>Hospital Universitari Germans Trias i Pujol, Badalona</description>
  </link>
  <link>
    <url>http://www.parcdesalutmar.cat</url>
    <description>Hospital Parc de Salut Mar, Barcelona</description>
  </link>
  <link>
    <url>http://www.santpau.es/</url>
    <description>Hospital de la Santa Creu i Sant Pau, Barcelona</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondylolisthesis</keyword>
  <keyword>Degenerative discopathy</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Tissue engineering</keyword>
  <keyword>Spinal fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

